Latest Mayne Pharma (Asx:Myx) News

The Treasurer has expressed preliminary concerns that Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma could harm Australia’s economy, citing plans to close a key Adelaide manufacturing site. Mayne Pharma disputes these claims and urges a resolution before the scheme deadline.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.

Mayne Pharma’s innovative oral contraceptive NEXTSTELLIS® has secured reimbursement under Australia’s Pharmaceutical Benefits Scheme, making it significantly more affordable and broadening contraceptive options nationwide.

Mayne Pharma has publicly refuted recent media claims about plans to close its Salisbury manufacturing site, clarifying its position amid ongoing regulatory scrutiny of its Scheme transaction with Cosette.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.